Suggested remit - To appraise the clinical and cost effectiveness of lisocabtagene maraleucel within its marketing authorisation for treating large B-cell Lymphoma after at least 2 therapies
Status In progress
Process STA 2018
ID number 1444

Provisional Schedule

Expected publication 09 December 2020

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
29 May 2019 - 26 June 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
10 May 2019 In progress, Referred 24 April 2017

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance